235 related articles for article (PubMed ID: 27211555)
1. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
[TBL] [Abstract][Full Text] [Related]
2. Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet!
Srivastava S; Deshpande D; Magombedze G; Gumbo T
Clin Infect Dis; 2018 Nov; 67(suppl_3):S359-S364. PubMed ID: 30496465
[TBL] [Abstract][Full Text] [Related]
3. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
5. Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps.
Deshpande D; Srivastava S; Pasipanodya JG; Bush SJ; Nuermberger E; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S80-S87. PubMed ID: 27742638
[TBL] [Abstract][Full Text] [Related]
6. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
7. [Pyrazinamide-containing initial intensive short course chemotherapy of pulmonary tuberculosis].
Wada M
Kekkaku; 1997 Oct; 72(10):587-95. PubMed ID: 9386358
[TBL] [Abstract][Full Text] [Related]
8. Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S88-S94. PubMed ID: 27742639
[TBL] [Abstract][Full Text] [Related]
9. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
10. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
11. Pyrazinamide plasma concentrations in young children with tuberculosis.
McIlleron H; Willemse M; Schaaf HS; Smith PJ; Donald PR
Pediatr Infect Dis J; 2011 Mar; 30(3):262-5. PubMed ID: 21416694
[TBL] [Abstract][Full Text] [Related]
12. [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Camacho A; Pérez-Camacho I; Rivero A; Natera C; García-Lázaro M; Castón JJ; Gallo M; Kindelán JM; Torre-Cisneros J
Enferm Infecc Microbiol Clin; 2010 Apr; 28(4):239-44. PubMed ID: 19647900
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
14. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
[TBL] [Abstract][Full Text] [Related]
15. Currently Used Low-Dose Pyrazinamide Does Not Increase Liver-Injury in the First Two Months of Tuberculosis Treatment.
Horita N; Miyazawa N; Yoshiyama T; Kojima R; Ishigatsubo Y; Kaneko T
Intern Med; 2015; 54(18):2315-20. PubMed ID: 26370854
[TBL] [Abstract][Full Text] [Related]
16. [DRUG-INDUCED LIVER INJURY AND PYRAZINAMIDE USE].
Horita N; Miyazawa N
Kekkaku; 2015 Mar; 90(3):401-5. PubMed ID: 26477109
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis.
El-Ridy MS; Mostafa DM; Shehab A; Nasr EA; Abd El-Alim S
Int J Pharm; 2007 Feb; 330(1-2):82-8. PubMed ID: 17049192
[TBL] [Abstract][Full Text] [Related]
18. Rifampin plus pyrazinamide-induced hepatitis requiring hospitalization in a 30-y-old male with latent tuberculosis.
Potolidis E; Mantadakis E; Zeniodi MH; Samonis G
Scand J Infect Dis; 2005; 37(2):155-7. PubMed ID: 15773037
[TBL] [Abstract][Full Text] [Related]
19. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
20. A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground.
Srivastava S; Deshpande D; Pasipanodya JG; Thomas T; Swaminathan S; Nuermberger E; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S75-S79. PubMed ID: 27742637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
